Because these data indicate that FXR agonism effectively reduced the severity of dyslipidemia caused by ritonavir, we have investigated in an independent set of experiments whether FXR gene ablation would exacerbate the dyslipidemia caused by the administration of this HIV-PI. The gene discussed is NR1H4; the disease is metabolic syndrome.